AbbVie, Boehringer to present promising data for Crohn’s research
The data suggest that Humira can be used to treat inflammatory bowel diseases, such as moderate or severe Crohn’s disease. The treatment appears safe for adults as well as children.
This data from the phase-two study determine whether this anti-IL-23 monoclonal biologic antibody can treat Crohn’s. The study results are promising.
AbbVie is a worldwide biopharmaceutical company. Its representatives will give 13 abstracts as presentations. The main topics will be Crohn’s disease and ulcerative colitis.
AbbVie and its collaborator, Boehringer Ingelhim, will also give presentations of the late-breaking data concerning risankizumab, which was previously called BI655066.
Additional research includes results from a seven-year interim study, the Pyramid post-marketing surveillance safety registry, which may be useful for determining the safety of patients using Humira to treat moderate to severe Crohn’s.
"AbbVie is committed to continued research in gastroenterology in order to make a significant impact on the lives of patients who face the burden inflammatory bowel diseases can have each day," Rob Scott, vice president of development and chief medical officer for AbbVie, said. "As leaders in immunology, we are focused on improving care for people living with these serious and chronic diseases."